Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
POOLED ANALYSIS OF THE EFFICACY OF BACILLE CALMETTE-GUERIN (BCG) IMMUNOTHERAPY IN MALIGNANT-MELANOMA
Autore:
TAN JKL; HO VC;
Indirizzi:
C-3955 TECUMSEH RD E WINDSOR N8W 1J5 ON CANADA UNIV BRITISH COLUMBIA,DIV DERMATOL VANCOUVER V6T 1W5 BC CANADA BRITISH COLUMBIA CANC AGCY VANCOUVER BC CANADA
Titolo Testata:
The Journal of dermatologic surgery and oncology
fascicolo: 11, volume: 19, anno: 1993,
pagine: 985 - 990
SICI:
0148-0812(1993)19:11<985:PAOTEO>2.0.ZU;2-J
Fonte:
ISI
Lingua:
ENG
Soggetto:
CUTANEOUS MELANOMA; RANDOMIZED TRIAL; ADJUVANT IMMUNOTHERAPY; STAGE-I; CHEMOTHERAPY; THERAPY; CANCER;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Science Citation Index Expanded
Science Citation Index Expanded
Science Citation Index Expanded
Citazioni:
33
Recensione:
Indirizzi per estratti:
Citazione:
J.K.L. Tan e V.C. Ho, "POOLED ANALYSIS OF THE EFFICACY OF BACILLE CALMETTE-GUERIN (BCG) IMMUNOTHERAPY IN MALIGNANT-MELANOMA", The Journal of dermatologic surgery and oncology, 19(11), 1993, pp. 985-990

Abstract

BACKGROUND. The trials of bacille Calmette-Guerin (BCG) as adjuvant therapy in malignant melanoma conducted over the preceding 2 decades have presented conflicting claims of efficacy. OBJECTIVE. Determination of the role of BCG immunotherapy in malignant melanoma. METHODS. Critical analysis of randomized clinical trials of stage I and II melanoma and all reported trials of intralesional and oral BCG in stage III melanoma was conducted. A literature search used the Medline data base (1966-1992); bibliographic reviews of relevant texts and pertinent articles. RESULTS. No significant benefit of BCG as postsurgical adjuvant therapy in stage I malignant melanoma was observed. Although two of seven trials in stage II melanoma demonstrated benefit with the addition of BCG, the trial with the greatest power in this series detected no difference in outcomes. In stage III malignant melanoma, there was no significant benefit with addition of BCG to various chemotherapeutic regimens. Oral BCG monotherapy produced complete responses in 6%, partial responses in 1%, and extended survival in 7% of patients. Objective responses were observed primarily in patients with intracutaneous non-visceral metastases. Pooled analysis of 15 non-controlled trials of intralesional BCG injections revealed complete responses in 19%, partialresponses in 26%, and extended survival in 13% of patients with stageIII melanoma. Objective responses to intralesional BCG were more likely in patients with solely cutaneous metastases, particularly intradermal lesions. CONCLUSION. Pooled analysis of non-placebo controlled trials of intralesional BCG for stage III malignant melanoma supports a trend to enhanced survival in patients with cutaneous non-visceral metastases.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 25/11/20 alle ore 10:18:58